60 Degrees Pharmaceuticals, Inc. (SXTP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.85
- As of
Kresmion compiles this page from SXTP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
60 DEGREES PHARMACEUTICALS, INC. (SXTP): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-27.
See the full SXTP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SXTP on one page. Preview it with sample data, then open it live with a free account.
Preview the SXTP dossierActive events for SXTP
- mediumEarnings below estimates
Q2-2026: Missed consensus by 29.8%, EPS $-0.90 vs $-0.6936 estimate
- mediumEarnings below estimates
Q2-2025: Missed consensus by 27.7% - EPS $-5 vs $-3.9168 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 46.5% - EPS $-2.64 vs $-4.9368 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 65.1% - EPS $-1.28 vs $-0.7752 estimate
FREE, NO ACCOUNT
Every event on SXTP, as it fires
New filings, 13F moves and cross asset events on SXTP land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SXTP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 83006G500 · 2026Q2 | $39K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SXTP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SXTP against its peers
SXTP's operating margin of -771.6% ranks in the 69th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | SXTP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.0M USD | 63167 USD | 83 | 8 |
| Gross margin | 22.3% | 81.5% | 21 | 6 |
| Operating margin | -771.6% | -5937.0% | 69 | 7 |
| Net margin | -732.5% | -5863.5% | 69 | 7 |
| Return on equity | -212.7% | -205.8% | 43 | 14 |
Peers (19): ERNA, CMND, CVKD, EOCN, BCAB, JUNS, SILO, APVO, GRI, KALA, EMMA, LSBCF.D, MBIO, HCWB, VIVS, PMCB, DCOY, CLDI, ABPO. Left out: BVAXF (no annual filing), VCNX (period gap), AGNPF (no annual filing), NYMXF (period gap), BIXT (no annual filing), GPLL (period gap). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (SXTP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SXTP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SXTP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.